Clinical Trials Logo

Filter by:
NCT ID: NCT05170464 Completed - Memory Deficits Clinical Trials

The Acute Effects of Exercise and Caffeine on Working Memory During Acute Caffeine Deprivation

Start date: January 10, 2022
Phase: Phase 2/Phase 3
Study type: Interventional

To determine the effects of moderate intensity exercise and caffeine on working memory in deprived caffeine consumers.

NCT ID: NCT05170204 Recruiting - Clinical trials for Non-Small Cell Lung Cancer

A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)

Start date: November 1, 2022
Phase: Phase 3
Study type: Interventional

This study will evaluate the efficacy and safety of multiple therapies in participants with locally advanced, unresectable, Stage III NSCLC with eligible biomarker status as determined by Version 8 of the American Joint Committee on Cancer/Union for International Cancer Control NSCLC staging system.

NCT ID: NCT05170087 Active, not recruiting - Breast Cancer Clinical Trials

Radiomic Analysis for Predicting Treatment Response and Clinical Outcomes in Malignancies

Start date: March 2, 2020
Phase:
Study type: Observational

In this study, the investigators aim to undertake a retrospective analysis of CT and MRI scans for patients undergoing radiation treatment to develop radiomic signatures to predict treatment response and clinical outcomes.

NCT ID: NCT05169892 Recruiting - Urologic Diseases Clinical Trials

Aquablation in Benign Prostatic Hyperplasia in Canada

Start date: October 9, 2019
Phase:
Study type: Observational

To document the clinical outcome of Aquablation therapy for BPH patient in Canadian cohort.

NCT ID: NCT05169710 Terminated - Clinical trials for Depressive Episodes, Bipolar I Depression

A Clinical Study of an Investigational Drug for the Treatment of Major Depressive Episode Associated With Bipolar I Disorder.

Start date: December 21, 2021
Phase: Phase 3
Study type: Interventional

A clinical trial to study the efficacy and safety of an investigational drug in people with major depressive episodes associated with with Bipolar I disorder (bipolar I depression) Participants in the study will either receive the drug being studied or a placebo. The study will be conducted in approximately 90 sites in North America, Europe, Latin America and Japan. It will be have both male and female participants ages 18-65. Participation in the study will be approximately 10 weeks.

NCT ID: NCT05169684 Completed - Clinical trials for Prostatic Neoplasms, Castration-Resistant

A Study of BMS-986218 or BMS-986218 Plus Nivolumab in Combination With Docetaxel in Participants With Metastatic Castration-resistant Prostate Cancer

Start date: February 14, 2022
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the safety, efficacy, tolerability, and toxicity of docetaxel alone, in combination with BMS-986218, or in combination with nivolumab plus BMS-986218 in men who have metastatic castration-resistant prostate cancer (mCRPC) that progressed after novel antiandrogen therapy and have not received chemotherapy for mCRPC.

NCT ID: NCT05169112 Recruiting - Prostate Cancer Clinical Trials

Impact of Hormonal Therapy on Prostate Cancer Recurrence After Radical Prostatectomy

Start date: March 6, 2023
Phase: Phase 3
Study type: Interventional

Prostate cancer is the most common cancer in men and radical prostatectomy is the most frequent treatment for this disease. Unfortunately, approximately 40% of patients will develop recurrence after surgery, requiring additional salvage radiation. Salvage radiation after recurrence is successful in less than half of these men and most of those die from their disease. Measures to prevent recurrence are an important research priority for prostate cancer patients and their families. Hormonal therapy (androgen deprivation therapy; ADT) is routinely used to treat patients with metastases, but few clinical trials have examined if adjuvant ADT after surgery will prevent cancer recurrence. We aim to address this research oversight and test the hypothesis that for men at high risk of cancer recurrence, 1 year of ADT immediately after surgery will be safe and will significantly improve cancer outcomes.

NCT ID: NCT05168644 Completed - Healthy Clinical Trials

Single Ascending Dose and Multiple Ascending Dose Study of Niclosamide Inhalation Powder in Healthy Adult Subjects

Start date: November 14, 2021
Phase: Phase 1
Study type: Interventional

This is a Phase 1 (healthy adult volunteers), 2-part, double-blind, randomized, placebo controlled trial to evaluate the safety and pharmacokinetic (PK) profiles of escalating single doses of Niclosamide Inhalation Powder versus placebo (SAD part) and escalating multiple doses of Niclosamide Inhalation Powder versus placebo (MAD part). SAD part will be initiated first and includes a sentinel design. MAD part will not utilize a sentinel design unless the data monitoring committee requests the addition of sentinels. The MAD part will be initiated once the lowest doses from SAD part are deemed safe.

NCT ID: NCT05168488 Completed - Type 1 Diabetes Clinical Trials

Repeatability of Blood Glucose Responses to Resistance Exercise in Type 1 Diabetes

Start date: November 16, 2021
Phase: N/A
Study type: Interventional

This study proposes to examine the impact of time of day (morning versus afternoon) on the variability of blood glucose responses to high resistance exercise in a single group of patients with type 1 diabetes. Participants will be asked to wear a continuous glucose monitor during the 3 weeks of testing. During the six exercise sessions (three in the morning while fasted and three in the afternoon), participants will complete the same resistance exercise protocol.

NCT ID: NCT05168371 Active, not recruiting - Clinical trials for Female Sexual Dysfunction

Cognitive-Behavioural & Mindfulness-Based Online Programs for Female Sexual Dysfunction

Start date: November 12, 2021
Phase: N/A
Study type: Interventional

Female sexual dysfunction (FSD) affects approximately one-third of women worldwide and is linked to negative physical, psychological, and interpersonal outcomes. Although both cognitive-behavioral therapy and mindfulness-based therapy are effective treatments for FSD, face-to-face treatments can be costly and are inaccessible to many people in remote areas. The goal of the current study is to pilot a randomized controlled trial to examine the effectiveness of and satisfaction with two online interventions for FSD. Women will be randomized to an online cognitive-behavioral program, an online mindfulness-based program, or a wait-list control group. Treatment will be administered entirely online and last 8-12 weeks. Women will meet weekly via Zoom with a navigator who will provide individualized support.